Equity Overview
Price & Market Data
Price: $85.66
Daily Change: +$3.33 / 3.89%
Daily Range: $78.28 - $85.95
Market Cap: $1,013,913,792
Daily Volume: 261,559
Performance Metrics
1 Week: 4.44%
1 Month: -8.79%
3 Months: 3.28%
6 Months: 69.83%
1 Year: 350.8%
YTD: -18.16%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country:
Details
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania